Department of Physical Therapy, University of Utah, Salt Lake City, UT, United States.
Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Adv Exp Med Biol. 2021;1321:109-113. doi: 10.1007/978-3-030-59261-5_9.
Endothelial cells are a clinically important infection site for COVID-19, both as a mechanism for disease pathogenesis and as a therapeutic target. People with dysfunctional endothelium, defined by nitric oxide deficiency, appear to have a more severe disease course. As such, nitric oxide has therapeutic potential to mitigate COVID-19 severity. Inhaled nitric oxide appears to improve outcomes, although this strategy neglects systemic endothelium. Meanwhile, early studies have documented that endothelial protective medications, such as the administration of statins and ACE-inhibitors, are associated with less severe disease and reduced mortality. Importantly, these medications augment endothelial sources of nitric oxide, which may explain this effect.
内皮细胞是 COVID-19 的一个重要临床感染部位，既是疾病发病机制的一种机制，也是一种治疗靶点。一氧化氮缺乏定义的功能失调内皮细胞的人似乎有更严重的疾病过程。因此，一氧化氮具有减轻 COVID-19 严重程度的治疗潜力。吸入一氧化氮似乎可以改善结果，尽管这种策略忽视了全身内皮细胞。与此同时，早期研究记录表明，内皮保护药物，如他汀类药物和 ACE 抑制剂的给药，与疾病程度较轻和死亡率降低有关。重要的是，这些药物增加了内皮细胞来源的一氧化氮，这可能解释了这种作用。
